Were there any safety concerns specific to angiotensin II (Giapreza®/AT2S) use?

Label:chem

Topic
Theoretical risks of AT2S include tachyarrhythmias and thrombosis due to potent vasoconstriction and platelet activation.
Answer
Safety events were rare and similar between groups. Only three thrombotic events occurred in the entire cohort, and just one happened while the patient was receiving AT2S. New-onset tachyarrhythmias were infrequent (atrial fibrillation: 3 Black vs. 6 non-Black, p = 0.635) and not statistically different between cohorts, indicating that AT2S did not confer excess arrhythmic or thrombotic risk.
Return to Home Chemical List
Knowledge you may be interested in
What is the role of synthetic angiotensin II (Giapreza®/AT2S) in the peri-operative management of kidney transplantation? What is the overall conclusion regarding CuE’s potential as an anti-obesity agent? What molecular pathways are implicated in CuE-mediated inhibition of adipogenesis and lipogenesis? Which key adipogenic transcription factors are down-regulated by Cucurbitacin E (CuE)? How does CuE influence lipid accumulation in differentiating 3T3-L1 adipocytes? Does Cucurbitacin E (CuE) exhibit cytotoxicity toward 3T3-L1 adipocytes during adipogenesis? What is Cucurbitacin E (CuE) and where is it derived from? Is the antiviral activity of zinc ions maintained across physiologically relevant temperatures? Does zinc-mediated inactivation compromise the structural integrity of the IAV particle? How do zinc ions affect influenza A virus (IAV) hemagglutinin function and virus infectivity? What is nicotine's proposed mechanism of neuroprotection in Parkinson’s disease (PD)? What were the findings of the meta-analysis regarding nicotine's effect on motor symptoms in PD patients? Did nicotine therapy improve activities of daily living (ADLs), quality of life (QoL), or cognition in PD patients? What limitations were identified in the clinical trials evaluating nicotine therapy for PD? What are the molecular targets of chlorogenic acid (CGA) and cinnamaldehyde (CA) in breast cancer cells? How strong are the binding interactions of CGA and CA with PI3K, Akt and PDK1 compared with FDA-approved drugs? What are the predicted oral absorption and bioavailability characteristics of CGA and CA? How are CGA and CA metabolized and cleared in vivo? What toxicological liabilities are predicted for CGA and CA? How do the physicochemical properties of CGA and CA influence their drug-likeness?